Yongan Pharmaceutical (002365.SZ) released its 2023 annual report. During the reporting period, the company achieved an operating income of 9...
According to the Zhitong Finance App, Yongan Pharmaceutical (002365.SZ) released its 2023 annual report. During the reporting period, the company achieved revenue of 973 million yuan, a year-on-year decrease of 33.48%. The net loss attributable to shareholders of the listed company was RMB 12.326 million. Net loss attributable to shareholders of the listed company after deducting non-recurring profit and loss was $75.9954 million. The basic loss per share was 0.0418 yuan. It is proposed to distribute a cash dividend of 1 yuan (tax included) for every 10 shares to all shareholders.
In 2023, the international situation became chaotic and intertwined, geopolitical conflicts intensified, protectionism and unilateralism rose, and global economic and trade growth was weak. The domestic economy is stable, moderate and improving, but it still faces challenges such as an uncertain foundation for economic recovery, insufficient effective demand, and weak social expectations. Faced with the complex and severe external environment and market situation, the company moved forward under pressure, overcame difficulties, and worked hard to stabilize management, strengthen innovation, improve quality, and ensure safety around the goal of high-quality development, and steadily carry out various businesses.